Evolving Evidence: Analysis of the Third NHMRC “Australian Report” on Homeopathy

In August 2024, Australia’s National Health and Medical Research Council (NHMRC) completed a new systematic review of homeopathy—one of 16 reviews commissioned by the Australian Government to assess the evidence for the effectiveness of a range of Natural Therapy modalities. The NHMRC 2024 homeopathy review concludes that, “For the populations (or conditions) assessed, homeopathy appears to provide little to no benefit when compared with placebo […] for most of the priority outcomes for which there is evidence available”. Given the ongoing debate around the status of the homeopathy evidence base, NHMRC’s review is likely to be widely cited. As such, it is necessary to gain a clear understanding of the methodology used, the review’s subsequent strengths and limitations, and the accuracy of the conclusions reached. From a preliminary analysis, it is apparent that the wording of the conclusion is inappropriate, as it fails to sufficiently reflect two aspects of the results: that is, the mixed nature of the findings and the very low level of certainty of the results overall. Furthermore, NHMRC’s findings need to be interpreted with appropriate consideration of the limited scope of this evaluation: of the 305 randomized controlled trials identified as suitable for review, only 93 trials were included (30%), covering only 20 of 136 conditions for which relevant evidence was available. Despite this significant limitation, the new “Australian Report” identified positive evidence for the effectiveness of homeopathy (moderate to low certainty) in at least five medical conditions, informing priorities for further research. This outcome is particularly notable when considered in the context of NHMRC’s two previous homeopathy reviews. The findings from a comparative analysis of the three “Australian Reports” (2012, 2015, and 2024) will be presented, examining the reasons for inconsistencies in their results and conclusions, which go beyond simple evolution of the clinical trial evidence base over time.